標(biāo)題: Titlebook: Antibody-Drug Conjugates; The 21st Century Mag Jeffrey Wang,Wei-Chiang Shen,Jennica L. Zaro Book 2015 American Association of Pharmaceutica [打印本頁] 作者: 貶損 時間: 2025-3-21 19:49
書目名稱Antibody-Drug Conjugates影響因子(影響力)
作者: promote 時間: 2025-3-21 22:52
https://doi.org/10.1007/978-3-642-71397-2get GPNMB, and is being investigated for its efficacy in metastatic breast cancer. This chapter reviews the mechanisms of action, preclinical, and phase I/II results of glembatumumab vedotin, and ongoing studies of its role in the treatment of breast cancer.作者: 不成比例 時間: 2025-3-22 01:46 作者: palette 時間: 2025-3-22 07:44 作者: HALL 時間: 2025-3-22 09:29
Hans Jürgen Matthies,Karl Theodor Reniusn of appropriate targets, the development of tools for antibody generation and screening, approaches to antibody isolation, advanced screening strategies for lead antibody selection, antibody engineering to increase selectivity and potency, and selection of appropriate combinations of linker, payload, and linker attachment strategy.作者: 骨 時間: 2025-3-22 15:36
https://doi.org/10.1007/978-3-322-87294-4eby inhibiting cell proliferation. Cytotoxicity of T-DM1 also arises upon binding of trastuzumab to HER2 by promoting antibody-dependent cell-mediated cytotoxicity and inhibiting HER2-dependent signaling pathways.作者: Decibel 時間: 2025-3-22 17:32 作者: 前兆 時間: 2025-3-22 23:17 作者: epicardium 時間: 2025-3-23 03:15
Hans Jürgen Matthies,Karl Theodor Renius and pharmacokinetic properties due to their complex and heterogeneous structures. The commonly used bioanalytical methods that are typically implemented to characterize various ADCs are summarized in this chapter. The challenges and perspectives of the assays are also discussed.作者: BRIEF 時間: 2025-3-23 07:28
https://doi.org/10.1007/978-3-658-06715-1oval clinical trials, the drug was voluntarily withdrawn by the market by Pfizer in June 2010. Since its withdrawal from the market, results from several clinical trials warrant revisiting the clinical use of the drug when used at a low-dose range in newly diagnosed AML with favorable cytogenetics.作者: Pageant 時間: 2025-3-23 11:44 作者: 抗原 時間: 2025-3-23 17:26 作者: medium 時間: 2025-3-23 20:23 作者: 上腭 時間: 2025-3-24 00:44 作者: delusion 時間: 2025-3-24 04:33 作者: averse 時間: 2025-3-24 07:09
Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cosovery and development. It summarizes the major players and programs in ADC drug development worldwide, currently running clinical trials registered in the USA, and recently published US patents and patent applications. In addition, the cost and outcomes aspects of ADC drug therapy are discussed.作者: otic-capsule 時間: 2025-3-24 14:17 作者: Incumbent 時間: 2025-3-24 18:20
Bioanalytical Assay for Characterization of Antibody-Drug Conjugates (ADCs) and pharmacokinetic properties due to their complex and heterogeneous structures. The commonly used bioanalytical methods that are typically implemented to characterize various ADCs are summarized in this chapter. The challenges and perspectives of the assays are also discussed.作者: Hemiparesis 時間: 2025-3-24 20:24 作者: laxative 時間: 2025-3-24 23:35 作者: 疏忽 時間: 2025-3-25 04:29 作者: 祖?zhèn)髫敭a(chǎn) 時間: 2025-3-25 08:04
Planung und Betrieb hydraulischer Anlagen,is chapter, we give an overview of ADC PKPD and disposition, and discuss our current understanding of the major determinants, unique challenges, and lessons learned from current ADC landscape. The utility of pharmacokinetics–pharmacodynamics (PKPD) modeling is also discussed in the context of provid作者: 無力更進(jìn) 時間: 2025-3-25 14:58
https://doi.org/10.1007/978-3-322-94107-7vering both areas with no specific CMC guidance for ADC products at this time. This chapter reviews some of the major regulatory considerations and issues for ADC development with emphasis on CMC challenges during early development (preclinical studies through phase 2 clinical proof of concept) and 作者: 言行自由 時間: 2025-3-25 17:44 作者: Osteons 時間: 2025-3-25 21:36
Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugatesis chapter, we give an overview of ADC PKPD and disposition, and discuss our current understanding of the major determinants, unique challenges, and lessons learned from current ADC landscape. The utility of pharmacokinetics–pharmacodynamics (PKPD) modeling is also discussed in the context of provid作者: 雕鏤 時間: 2025-3-26 03:10
Regulatory Considerationsvering both areas with no specific CMC guidance for ADC products at this time. This chapter reviews some of the major regulatory considerations and issues for ADC development with emphasis on CMC challenges during early development (preclinical studies through phase 2 clinical proof of concept) and 作者: obnoxious 時間: 2025-3-26 07:26 作者: Tractable 時間: 2025-3-26 12:26
2210-7371 me presents a perspective by the editors on the future directions of ADC development and clinical applications. .Antibody-Drug Conjugates. is a practical and systematic resource for scientists, professors, and 978-3-319-37669-1978-3-319-13081-1Series ISSN 2210-7371 Series E-ISSN 2210-738X 作者: accessory 時間: 2025-3-26 14:02 作者: Enliven 時間: 2025-3-26 17:08
Antibody-Drug Conjugates978-3-319-13081-1Series ISSN 2210-7371 Series E-ISSN 2210-738X 作者: 走路左晃右晃 時間: 2025-3-26 21:51
Hans Jürgen Matthies,Karl Theodor Reniusansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs. The structures, mechanisms of action, pharmacokinetics, and toxicities of these toxins are reviewed and discussed. The payloads along with the clinically tested ADCs and their therapeutic areas are summarized.作者: Mobile 時間: 2025-3-27 05:02 作者: 女歌星 時間: 2025-3-27 06:04
AAPS Advances in the Pharmaceutical Sciences Serieshttp://image.papertrans.cn/a/image/158481.jpg作者: Cholagogue 時間: 2025-3-27 10:54
https://doi.org/10.1007/978-3-319-13081-1antibody; bio-analysis; immunotoxin; linkers; payloads作者: anaphylaxis 時間: 2025-3-27 17:18
978-3-319-37669-1American Association of Pharmaceutical Scientists 2015作者: happiness 時間: 2025-3-27 19:40
,Elemente und Ger?te zur Energieübertragung,t of antibody-mediated “magic bullets.” Progress of ADC development correlated closely with the advances of the knowledge and technology in immunology, conjugation chemistry, molecular biology, and cell biology. Results from diverse studies in different scientific disciplines during the past half ce作者: Conducive 時間: 2025-3-28 01:10 作者: phase-2-enzyme 時間: 2025-3-28 02:09 作者: Brochure 時間: 2025-3-28 08:39 作者: 改變 時間: 2025-3-28 11:42
Hans Jürgen Matthies,Karl Theodor Reniusg an antibody with small cytotoxic drugs generally either through lysine ε-amino groups to form a lysine-linked ADC or through sulfhydryl groups of reducing interchain cystine. THIOMAB?–drug conjugates (TDCs) are a new subclass of ADCs in which the engineered free cysteine residues at specific sites作者: configuration 時間: 2025-3-28 17:40 作者: 充氣球 時間: 2025-3-28 22:46 作者: ostrish 時間: 2025-3-29 01:33 作者: Accessible 時間: 2025-3-29 07:05 作者: 仇恨 時間: 2025-3-29 08:13
https://doi.org/10.1007/978-3-658-06715-1d Drug Administration (FDA) via the accelerated approval process in 2000. Mylotarg. consists of an antibody directed toward the CD33 antigen conjugated to the antitumor antibiotic, calicheamicin. Mainly due to concerns about the safety profile and lack of improvement of clinical benefit in post-appr作者: FILTH 時間: 2025-3-29 12:48
Zum methodischen Vorgehen Max Webers,gust 2011, it became only the second ADC approved by the FDA and the only one on the market at that time following the withdrawal of Mylotarg (gentuzumab ozogamycin) in June 2010. The development pathway incorporated nearly all of the FDA incentive development pathways including fast-track and orpha作者: 白楊 時間: 2025-3-29 16:04
https://doi.org/10.1007/978-3-322-87294-4ial cancer cells overexpressing the oncoprotein HER2. T-DM1 has been approved in many countries for HER2-positive metastatic breast cancer (MBC) patients and has recently entered a phase 3 clinical trial for advanced HER2-positive gastric cancer patients. The success of T-DM1 lies in the optimizatio作者: NATAL 時間: 2025-3-29 22:04
https://doi.org/10.1007/978-3-642-71397-2types of breast cancers, triple-negative breast cancer (TNBC) is especially challenging due to fewer treatment options and more aggressive clinical course. Therefore, the development of molecularly targeted therapies for TNBC is crucial. Glycoprotein nonmetastatic B (GPNMB) is overexpressed in many 作者: Calculus 時間: 2025-3-30 02:53
Antibody-Drug Conjugates: A Historical Reviewt of antibody-mediated “magic bullets.” Progress of ADC development correlated closely with the advances of the knowledge and technology in immunology, conjugation chemistry, molecular biology, and cell biology. Results from diverse studies in different scientific disciplines during the past half ce作者: ANTE 時間: 2025-3-30 07:05 作者: AV-node 時間: 2025-3-30 10:04
Selecting an Optimal Antibody for Antibody- Drug Conjugate Therapygy indications. ADC-based therapies are attractive due to their potential to increase efficacy and reduce the systemic toxicity produced by other conventional anticancer regimens. ADCs are complex molecules, however, and their clinical success depends both on properties of the target in the context 作者: 休戰(zhàn) 時間: 2025-3-30 12:36
